Health Care Financing Administration wants a report from all Medicare regional carriers on drug-pricing practices within 30 days, April 17 memo says. HCFA is performing an analysis of Medicare drug pricing "to determine whether and the extent to which contractor pricing actually varies," the memo states. Data on sources used by contractors to determine average wholesale price, methodologies to calculate 95% of AWP and actual Medicare-allowed amounts for all Medicare covered drugs are to be collected. HCFA adopted revised AWPs using wholesaler catalog prices compiled by the Department of Justice but later suspended implementation (1"The Pink Sheet" Nov. 27, 2000, p. 4)
You may also be interested in...
The Health Care Financing Administration is suspending implementation of a new average wholesale price list for drugs covered by Medicare for one year.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials